Ancillary Study to Protocol 20060104

Amgen50 enrolled

Overview

Ancillary study to the Etanercept protocol 20060104. Subjects have been asked to provide additional blood samples for further assessment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

Blood drawPROCEDURE

blood draw at baseline, week 12 and week 24

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed Consent Meet all inclusion critieria outlined in Amgen Protocol 20060104 Exclusion Criteria: * Meet exclusion criteria outlined in Amgen Protocol 20060104

Outcomes

Primary Outcomes

To explore the correlation between pheripheral blood cell protein phosphorylation assessemnts and rheumatoid arthritis disease activity.

Time frame: week 24

Secondary Outcomes

Explore the correlations to etanercept clinical response (ACR and DAS scores) may also be explored.

Time frame: week 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.